Wednesday, June 13, 2012 3:17:49 PM
Clarity & Closure
First and foremost, David Rifkin has not supplied me with any “inside information” regarding ATRN. David and I have a professional relationship that stems from conversations related to potential synergies within our respective networks – not ATRN’s status as a viable, operating company. Assumptions based on our LinkedIn and/or Facebook connection is egregious.
My post yesterday was 100% factual in the sense that it’s what I believe to be true based on my own DD. Meaning, I was not making up any of the information in an effort to manipulate the share price. My sources were credible enough (in my mind) to drive me (and those who trust me) out of their positions. It’s important to understand that my professional network contains a wide array of individuals who are connected to the interactive agency world in a variety of ways (as clients, employees, partners, prospects, etc.). This is truly a case of there being only six degrees of separation.
To doubt my DD is your prerogative. It’s your money. However, I have chosen to rely on my DD, along w/ RoagTrader’s DD after his visit to ATRN HQ, the 2 most recent PR’s, the fact that I don’t believe ATRN has any “code” to sell (they are an agency, not a tech company. How many ATRN employees on LinkedIn have job titles related to Software Development?), and finally, the unsettling feeling that there is no foreseeable path to a profitable PPS at an ACB in the teens.
Best of luck to all of you. Since I am no longer holding a position in ATRN, this will be my last public post. I can’t reply to PM’s and I’ve been banned. If you have a reply, I am sure one of the guys can give you my email address. But please, don’t throw people under the bus who don’t have anything to do with information conveyed in yesterdays post.
First and foremost, David Rifkin has not supplied me with any “inside information” regarding ATRN. David and I have a professional relationship that stems from conversations related to potential synergies within our respective networks – not ATRN’s status as a viable, operating company. Assumptions based on our LinkedIn and/or Facebook connection is egregious.
My post yesterday was 100% factual in the sense that it’s what I believe to be true based on my own DD. Meaning, I was not making up any of the information in an effort to manipulate the share price. My sources were credible enough (in my mind) to drive me (and those who trust me) out of their positions. It’s important to understand that my professional network contains a wide array of individuals who are connected to the interactive agency world in a variety of ways (as clients, employees, partners, prospects, etc.). This is truly a case of there being only six degrees of separation.
To doubt my DD is your prerogative. It’s your money. However, I have chosen to rely on my DD, along w/ RoagTrader’s DD after his visit to ATRN HQ, the 2 most recent PR’s, the fact that I don’t believe ATRN has any “code” to sell (they are an agency, not a tech company. How many ATRN employees on LinkedIn have job titles related to Software Development?), and finally, the unsettling feeling that there is no foreseeable path to a profitable PPS at an ACB in the teens.
Best of luck to all of you. Since I am no longer holding a position in ATRN, this will be my last public post. I can’t reply to PM’s and I’ve been banned. If you have a reply, I am sure one of the guys can give you my email address. But please, don’t throw people under the bus who don’t have anything to do with information conveyed in yesterdays post.
Recent PTIX News
- Protagenic Therapeutics Completes Phytanix Separation, Strengthens Balance Sheet and Repositions the Company Around PT00114 • ACCESS Newswire • 03/17/2026 12:00:00 PM
- Protagenic Therapeutics Upgrades from OTC Pink to OTCQB Venture Market • ACCESS Newswire • 03/10/2026 12:00:00 PM
- Results from Phase 1 Multiple-Dose Study of PT00114 • ACCESS Newswire • 12/09/2025 01:46:00 PM
- Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice • ACCESS Newswire • 11/27/2025 08:45:00 AM
- Protagenic Therapeutics Announces Completion of Enrollment and Dosing in Phase 1 MAD Study • ACCESS Newswire • 11/13/2025 01:22:00 PM
- Protagenic Therapeutics Announces Grant of new patent in Japan for its Modified Stilbenoid Program Drug Candidates • GlobeNewswire Inc. • 07/30/2025 12:30:00 PM
- Nasdaq Top 5 Premarket Losers • IH Market News • 05/20/2025 12:47:37 PM
- Protagenic Therapeutics Soars 190% on Merger to Launch Neuroactive Biopharma Firm • IH Market News • 05/19/2025 02:28:09 PM
- Nasdaq Top 5 Premarket Gainers • IH Market News • 05/19/2025 01:07:08 PM
